

Ulcerative Colitis - Pipeline Insight, 2021

<https://marketpublishers.com/r/U30575834BF9EN.html>

Date: May 2021

Pages: 200

Price: US\$ 2,500.00 (Single User License)

ID: U30575834BF9EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Ulcerative Colitis - Pipeline Insight, 2021," report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Ulcerative Colitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Ulcerative Colitis Understanding

Ulcerative Colitis: Overview

Ulcerative colitis is a chronic disease of the large intestine, in which the lining of the colon become inflamed and develop tiny open sores or ulcers. Those ulcers produce pus and mucus, which causes abdominal pain. It usually begins in the rectum and spreads upwards. The inflammation causes bowel to move its content rapidly and empty frequently. Ulcerative colitis begins gradually and become worse over the period of time. Ulcerative colitis also known as inflammatory bowel disease.

Ulcerative colitis symptoms range from mild to severe and varies among affected people. The predominant symptoms in ulcerative colitis is diarrhea, which can be associated with the discharge of blood in the stool. Diarrhea is the dominant complaint

in patients suffering from this disease. The patients suffer from frequent bowel movements, which may be small in volume which results to irritability of the inflamed rectum. Other symptoms of ulcerative colitis include abdominal or rectal pain, fever and weight loss. It also causes joint pain, joint swelling, skin problems and eye inflammation.

Accurate and timely diagnosis of ulcerative colitis is important to initiate appropriate treatment. The treatment of ulcerative colitis is multifaceted and includes the use of medications, alterations in diet and nutrition and some surgical procedures to repair or remove affected portions of gastrointestinal tract. Most patients with ulcerative colitis can be managed at the outpatient clinic and treated successfully. Medications such as Beclomethasone propionate and budesonide MMX, are preferred over systemic steroids owing to their superior safety profile.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ulcerative Colitis R&D. The therapies under development are focused on novel approaches for Ulcerative Colitis.

Ulcerative Colitis Emerging Drugs Chapters

This segment of the Ulcerative Colitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ulcerative Colitis Emerging Drugs

Etrasimod: Arena Pharmaceuticals

Etrasimod is a next-generation, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator with an optimized S1P receptor activity profile. Etrasimod selectively targets S1P receptor subtypes 1, 4 and 5 which have been implicated in decreasing intestinal inflammation. Etrasimod does not activate S1P2 or S1P3 receptor subtypes, which are associated with cardiac, pulmonary and tumor-related side effects. Etrasimod provides systemic and local effects on specific immune cell types and has the potential to treat multiple immune-mediated inflammatory diseases, including ulcerative colitis,

Crohn's disease, atopic dermatitis and alopecia areata.

It is currently in phase III stage of development for Ulcerative colitis and is being developed by Arena Pharmaceuticals.

Upadacitinib: Abbvie

Upadacitinib (ABT-494) is an oral, once daily, selective and reversible JAK inhibitor studied in several immune-mediated inflammatory diseases. It possess greater inhibitory potency for JAK1 versus JAK2, JAK3 and TYK2. JAK1 inhibition blocks the signaling of many important pro-inflammatory cytokines like interleukin IL-2, IL-6, IL-7, and IL-15, which are known to contribute for inflammatory disorders.

In 2019, RINVOQ (Upadacitinib) received USFDA and European Commission approval for adult patients with moderately to severely active rheumatoid arthritis who are intolerant to one or more disease-modifying anti-rheumatic drugs. Upadacitinib is currently under Phase 3 clinical studies for the treatment of atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing.

Further product details are provided in the repor

Ulcerative Colitis: Therapeutic Assessment

This segment of the report provides insights about the different Ulcerative Colitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Ulcerative Colitis

There are approx. 100+ key companies which are developing the Ulcerative Colitis. The companies which have their Ulcerative Colitis drug candidates in the most advanced stage, i.e. Phase III include, Arena Pharmaceuticals.

Phases

DelveInsight's report covers around 110+ products under different phases of clinical

development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Ulcerative Colitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ulcerative Colitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Ulcerative Colitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ulcerative Colitis drugs.

Ulcerative Colitis Report Insights

Ulcerative Colitis Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Ulcerative Colitis Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Ulcerative Colitis drugs?

How many Ulcerative Colitis drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Ulcerative Colitis?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Ulcerative Colitis therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Ulcerative Colitis and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

AbbVie

Celgene

Eli Lilly and Company

Lipid Therapeutics

Hoffmann-La Roche

Arena Pharmaceuticals

InDex Pharmaceuticals

EA Pharma

FYB202 GmbH & Co KG

Theravance Biopharma

Boehringer Ingelheim

Janssen Research & Development

Lycera

Eli Lilly and Company

LG Chem

Iltoo Pharma

Immunic

Hutchison Medipharma

Tianjin Hemay Pharmaceutical

GlaxoSmithKline

Gilead Sciences

Gossamer Bio

Eisai

UCB

Suzhou Connect Biopharmaceuticals

Landos Biopharma

Seres Therapeutics

Abivax

Genentech, Inc.

ParaTech A/S

I-Mab Biopharma HongKong Limited

Sublimity Therapeutics Holdco Limited|Dr. Falk Pharma GmbH

Reistone Biopharma Company Limited

Qu Biologics Inc.

PurGenesis Technologies Inc.

Protagonist Therapeutics, Inc.

Pfizer

Palobiofarma SL

Novartis Pharmaceuticals

Bristol-Myers Squibb

Bridge Biotherapeutics

Amgen

Applied Molecular Transport

AbGenomics International, Inc.

Protalix BioTherapeutics

LTT Bio-Pharma Co Ltd

Dongwha pharma

Seres Therapeutics

Innovation Pharmaceuticals

Holy Stone Healthcare

SLA Pharma

OSE Immunotherapeutics

Bridge Biotherapeutics

Mitsubishi Tanabe Pharma

Sterna Biologicals GmbH

Mesoblast

Oncostellae

First Wave Bio

Key Products

Upadacitinib

Ozanimod

Risankizumab

Mirikizumab

LT-02

Etrolizumab

Etrasimod

Cobitolimod

AJM 300

FYB 202

TD-1473

Spesolimab

Guselkumab

LYC-30937

LY3471851

LC51-0255

Aldesleukin

IMU-838

HMPL-004

Hemay007

GSK2831781

GS-4875

GLPG3970

GED-0301

GB-004

E6007

Cimzia

CBP-307

BT-11

Vancomycin

ABX464

UTTR1147A

Trichuris suis ova

TJ301

ST-0529

SHR0302

QBECO SSI

PUR 0110

PN-943

PF-06687234

PF-06651600

PF-06480605

PBF-677

LYS 006

BMS-986165

BBT-401-1S

Apremilast

Brazikumab

AMT-101

AbGn-168H

ABBV-323

OPRX-106

LT 0011

DW2007

SER-287

Brilacidin

IBD98

ALFA

OSE-127

BBT-401

Amiselimod

SB012

Remestemcel-L

OST-122

Niclosamide

Contents

- Introduction
- Executive Summary
- Ulcerative Colitis: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Ulcerative Colitis– DelveInsight's Analytical Perspective
- In-depth Commercial Assessment
 - Ulcerative Colitis companies' collaborations, Licensing, Acquisition -Deal Value
- Trends
- Ulcerative Colitis Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- Etrasimod: Arena Pharmaceuticals
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Mid Stage Products (Phase II)
 - Comparative Analysis
- ABBV-323: AbbVie
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Early Stage Products (Phase I)
 - Comparative Analysis

AK 101: Akeso Biopharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Preclinical and Discovery Stage Products

Comparative Analysis

FIN-524: Finch Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Ulcerative Colitis Key Companies

Ulcerative Colitis Key Products

Ulcerative Colitis- Unmet Needs

Ulcerative Colitis- Market Drivers and Barriers

Ulcerative Colitis- Future Perspectives and Conclusion

Ulcerative Colitis Analyst Views

Ulcerative Colitis Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Ulcerative Colitis

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Ulcerative Colitis
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Ulcerative Colitis - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/U30575834BF9EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/U30575834BF9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970